WO1999036536A3 - Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial - Google Patents
Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial Download PDFInfo
- Publication number
- WO1999036536A3 WO1999036536A3 PCT/US1999/001087 US9901087W WO9936536A3 WO 1999036536 A3 WO1999036536 A3 WO 1999036536A3 US 9901087 W US9901087 W US 9901087W WO 9936536 A3 WO9936536 A3 WO 9936536A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- clearance
- compositions
- methods
- cell death
- programmed cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000027418 Wounds and injury Diseases 0.000 title 1
- 238000003782 apoptosis assay Methods 0.000 title 1
- 230000006378 damage Effects 0.000 title 1
- 208000014674 injury Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 title 1
- 230000005522 programmed cell death Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 4
- 230000035899 viability Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU23262/99A AU2326299A (en) | 1998-01-20 | 1999-01-19 | Methods and compositions to alter tissue susceptibility to immune injury, to programmed cell death, and to clearance by the reticuloendothelial system |
EP99903179A EP1047779A2 (fr) | 1998-01-20 | 1999-01-19 | Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7195098P | 1998-01-20 | 1998-01-20 | |
US60/071,950 | 1998-01-20 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1999036536A2 WO1999036536A2 (fr) | 1999-07-22 |
WO1999036536A9 WO1999036536A9 (fr) | 1999-11-04 |
WO1999036536A3 true WO1999036536A3 (fr) | 1999-12-09 |
Family
ID=22104619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/001087 WO1999036536A2 (fr) | 1998-01-20 | 1999-01-19 | Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1047779A2 (fr) |
AU (1) | AU2326299A (fr) |
WO (1) | WO1999036536A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030139359A1 (en) * | 2001-12-04 | 2003-07-24 | Isis Pharmaceuticals Inc. | Antisense modulation of phospholipid scramblase 3 expression |
US20030044979A1 (en) * | 2001-04-05 | 2003-03-06 | Isis Pharmaceuticals Inc. | Antisense modulation of phospholipid scramblase I expression |
IL147812A0 (en) * | 2001-03-16 | 2002-08-14 | N S T Neurosurvival Technologi | Method for targeting chemical compounds to cells and pharmaceutical compositions used therein |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997037225A1 (fr) * | 1996-04-02 | 1997-10-09 | Blood Center Research Foundation | PREPARATION D'UNE PROTEINE QUI CONTROLE LE MOUVEMENT Ca2+-DEPENDANT DES PHOSPHOLIPIDES DES MEMBRANES PLASMIQUES A TRAVERS LES COUCHES DOUBLES ET INHIBITEURS DE CETTE PROTEINE |
WO1999019352A2 (fr) * | 1997-10-10 | 1999-04-22 | Blood Center Research Foundation | Methodes et compositions permettant de modifier l'expression de la surface cellulaire de la phosphatidylserine et d'autres phospholipides de membrane plasmique favorisant la formation de caillots |
-
1999
- 1999-01-19 WO PCT/US1999/001087 patent/WO1999036536A2/fr not_active Application Discontinuation
- 1999-01-19 EP EP99903179A patent/EP1047779A2/fr not_active Withdrawn
- 1999-01-19 AU AU23262/99A patent/AU2326299A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997037225A1 (fr) * | 1996-04-02 | 1997-10-09 | Blood Center Research Foundation | PREPARATION D'UNE PROTEINE QUI CONTROLE LE MOUVEMENT Ca2+-DEPENDANT DES PHOSPHOLIPIDES DES MEMBRANES PLASMIQUES A TRAVERS LES COUCHES DOUBLES ET INHIBITEURS DE CETTE PROTEINE |
WO1999019352A2 (fr) * | 1997-10-10 | 1999-04-22 | Blood Center Research Foundation | Methodes et compositions permettant de modifier l'expression de la surface cellulaire de la phosphatidylserine et d'autres phospholipides de membrane plasmique favorisant la formation de caillots |
Non-Patent Citations (11)
Also Published As
Publication number | Publication date |
---|---|
WO1999036536A2 (fr) | 1999-07-22 |
WO1999036536A9 (fr) | 1999-11-04 |
EP1047779A2 (fr) | 2000-11-02 |
AU2326299A (en) | 1999-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000024365A8 (fr) | Traitement de la peau au moyen d'adenosine ou d'un analogue d'adenosine | |
WO2001073032A3 (fr) | Compositions et methodes de therapie et de diagnostic du cancer de la prostate | |
EP1146046A3 (fr) | Pyrophéophorbides et leur utilisation en thérapie photodynamique | |
EP1353288A3 (fr) | Système de modélisation biologique hiérarchisé et procédé associé | |
WO2002014503A3 (fr) | Compositions et methodes de traitement et de diagnostic de cancers associes a her-2/neu | |
WO1998019167A3 (fr) | Gene de classe i du complexe majeur d'histocompatibilite humain a stress cellulaire regule | |
WO2000015247A8 (fr) | Traitement du myelome multiple et de la resorption osseuse provoquee par le myelome au moyen d'antagonistes de l'interaction -cam-1/vla-4 | |
AU3549697A (en) | Extracting particles produced by the treating of human or animal nails | |
WO2000029002A3 (fr) | Transplantation intra-uterine de cellules embryonnaires mesenchymateuses humaines | |
CA2098113A1 (fr) | Substances de nature polypeptidique pour usage therapeutique chez l'homme | |
BR9903750B1 (pt) | utilização não terapêutica de pelo menos um extrato de rosácea do gênero sanguisorba e processo cosmético de pigmentação da pele. | |
BR9612821A (pt) | Métodos para a prevenção de rejeição de enxerto em transplante e para a produção de uma célula de hospedeiro para terapia genética universal | |
DE69831404D1 (de) | Verwendung von mindestens einem irvingia gabonensis-extrakt in kosmetischen und/oder pharmazeutischen produkten | |
WO1999036536A3 (fr) | Methodes et compositions permettant de modifier la sensibilite des tissus face aux lesions immunitaires, a la mort cellulaire programmee et a la clairance par le systeme reticulo-endothelial | |
WO2005047469A3 (fr) | Proteine isogloboside 3 synthase porcine, adnc, organisation genomique, et region regulatrice | |
WO2001077168A3 (fr) | Compositions et procedes permettant de traiter et de diagnostiquer le cancer du poumon | |
WO2000047231A3 (fr) | Nouvelle inhibition antisens de rad51 | |
WO2003079884A3 (fr) | Methodes de diagnostic et de pronostic du cancer | |
WO2003007900A3 (fr) | Traitement de la peau | |
WO2003098223A3 (fr) | Nouvelles therapies et procedes de criblage de composes therapeutiques | |
TW200718944A (en) | Screening methods for compounds that affect melanogenesis | |
EP1696028A3 (fr) | Compositions et méthodes pour la thérapie et le diagnostic du cancer du sein | |
EP1046397A3 (fr) | Nouvelle substance bioactivatrice | |
WO2001054707A3 (fr) | Utilisation d'au moins un inhibiteur d'aminopeptidase | |
WO2003068160A3 (fr) | Utilisation de la proteine 3 (igf-bp3) de facteur de croissance de type insuline dans le but d'inhiber la croissance d'une tumeur |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/16-16/16, DRAWINGS, REPLACED BY NEW PAGES 1/20-20/20; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999903179 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09600535 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999903179 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999903179 Country of ref document: EP |